An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-06

AUTHORS

Paul Tappenden, Susannah Sadler, Martin Wildman

ABSTRACT

BACKGROUND: Cystic fibrosis (CF) negatively impacts upon health-related quality of life and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline. OBJECTIVE: A state transition model was developed to assess the cost effectiveness of an intervention aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT). METHODS: The model estimated the costs and health outcomes for each option from the perspective of the UK National Health Service and Personal Social Services over a lifetime horizon. Health gains were valued in terms of quality-adjusted life-years (QALYs) gained. Forced expiratory volume in 1 second (FEV1) trajectories were predicted over three lung function strata: (1) FEV1 ≥70%, (2) FEV1 40-69% and (3) FEV1 <40%. Additional states were included to represent 'post-lung transplantation' and 'dead'. The model was populated using CF Registry data, literature and expert opinion. Costs were presented at 2016 values. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. RESULTS: If effective, the adherence intervention is expected to produce an additional 0.19 QALYs and cost savings of £64,078 per patient. Across all analyses, the intervention dominated current care. Over a 5-year period, the intervention is expected to generate cost savings of £49.5 million for the estimated 2979 patients with CF with Pseudomonas aeruginosa currently aged ≥16 years in the UK. If applied to a broader population of adult patients with CF receiving any nebulised therapy, the expected savings could be considerably greater. CONCLUSIONS: If effective, the adherence intervention is expected to produce additional health gains at a lower cost than current CF care. However, the economic analysis should be revisited upon completion of the full RCT. More generally, the analysis suggests that considerable gains could be accrued through the implementation of adherence interventions that shift care from expensive hospital-based rescue to community-based prevention. More... »

PAGES

647-659

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40273-017-0500-x

DOI

http://dx.doi.org/10.1007/s40273-017-0500-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084038600

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28337719


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost Savings", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cystic Fibrosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Forced Expiratory Volume", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medication Adherence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Economic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pseudomonas Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pseudomonas aeruginosa", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tappenden", 
        "givenName": "Paul", 
        "id": "sg:person.0670022306.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670022306.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sadler", 
        "givenName": "Susannah", 
        "id": "sg:person.013631641755.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013631641755.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sheffield Teaching Hospitals NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.31410.37", 
          "name": [
            "Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wildman", 
        "givenName": "Martin", 
        "id": "sg:person.01335407753.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335407753.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40273-013-0122-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003917451", 
          "https://doi.org/10.1007/s40273-013-0122-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.39391.713229.ad", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005785125"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04167.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006076798"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.09-3074", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006892365"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2288-12-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010370832", 
          "https://doi.org/10.1186/1471-2288-12-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ppul.23344", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012408786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcf.2012.10.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012742686"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jcf.2008.09.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015405522"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thorax.56.3.218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015966584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/thorax.56.3.218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015966584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa043900", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020381896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-013-0041-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023748951", 
          "https://doi.org/10.1007/s40265-013-0041-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-013-0041-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023748951", 
          "https://doi.org/10.1007/s40265-013-0041-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1183/09031936.00099506", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024574270"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.13-1926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042282240"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1164/rccm.200812-1845pp", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042486144"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/ppa.s105530", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044618897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3310/hta17560", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071139376"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-06", 
    "datePublishedReg": "2017-06-01", 
    "description": "BACKGROUND: Cystic fibrosis (CF) negatively impacts upon health-related quality of life and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline.\nOBJECTIVE: A state transition model was developed to assess the cost effectiveness of an intervention aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT).\nMETHODS: The model estimated the costs and health outcomes for each option from the perspective of the UK National Health Service and Personal Social Services over a lifetime horizon. Health gains were valued in terms of quality-adjusted life-years (QALYs) gained. Forced expiratory volume in 1 second (FEV1) trajectories were predicted over three lung function strata: (1) FEV1\u00a0\u226570%, (2) FEV1 40-69% and (3) FEV1\u00a0<40%. Additional states were included to represent 'post-lung transplantation' and 'dead'. The model was populated using CF Registry data, literature and expert opinion. Costs were presented at 2016 values. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses.\nRESULTS: If effective, the adherence intervention is expected to produce an additional 0.19 QALYs and cost savings of \u00a364,078 per patient. Across all analyses, the intervention dominated current care. Over a 5-year period, the intervention is expected to generate cost savings of \u00a349.5 million for the estimated 2979 patients with CF with Pseudomonas aeruginosa currently aged \u226516\u00a0years in the UK. If applied to a broader population of adult patients with CF receiving any nebulised therapy, the expected savings could be considerably greater.\nCONCLUSIONS: If effective, the adherence intervention is expected to produce additional health gains at a lower cost than current CF care. However, the economic analysis should be revisited upon completion of the full RCT. More generally, the analysis suggests that considerable gains could be accrued through the implementation of adherence interventions that shift care from expensive hospital-based rescue to community-based prevention.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40273-017-0500-x", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5149589", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1102812", 
        "issn": [
          "1170-7690", 
          "1179-2027"
        ], 
        "name": "PharmacoEconomics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis", 
    "pagination": "647-659", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7790f8437bb7a467d4580bae2e758445f740ac9e3a31367a910449128367b3b1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28337719"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9212404"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40273-017-0500-x"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084038600"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40273-017-0500-x", 
      "https://app.dimensions.ai/details/publication/pub.1084038600"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89798_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs40273-017-0500-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40273-017-0500-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40273-017-0500-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40273-017-0500-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40273-017-0500-x'


 

This table displays all metadata directly associated to this object as RDF triples.

211 TRIPLES      21 PREDICATES      63 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40273-017-0500-x schema:about N0151544d194c44fc9bef0caf5158a361
2 N0f4ad24473fb4633abd8fcda08579f67
3 N12c70d32fdc94181abe4bcfaef08a663
4 N17d0863343a14300a917320c3e9a5907
5 N198213cb69344fda8596045ea40218cb
6 N22d28543846b47fe81c34aa7d6d632a3
7 N2faf5897d7244600bf0c946b1616a6e0
8 N39b78ec304fa46afaaac9a8b66243e16
9 N7196a1ed932042dab5b1738d09070a8d
10 N837a2b1ce1094b10b0dd1775bd06b4a5
11 N86871a48e0af422dbc6470806f7f86bf
12 N9723ff385cd54c1e9cc29ed9092cc316
13 Na46e39def98b48fc8bc6551976e8a2b2
14 Nae87c0b5d8cf411ea74353b20323bd6b
15 Nc2ad4dcfef2746b69b66484e3c50d02c
16 Nc3a208fbf45f4ae0b58a7b7b16b888d7
17 Nc58d3973f2f9446f9427cf60feda74f3
18 Nf7853111076a46048749dc88f5f849c0
19 anzsrc-for:11
20 anzsrc-for:1117
21 schema:author N8076cff925f046e59e19b9562a1f6fd5
22 schema:citation sg:pub.10.1007/s40265-013-0041-3
23 sg:pub.10.1007/s40273-013-0122-x
24 sg:pub.10.1186/1471-2288-12-9
25 https://doi.org/10.1002/ppul.23344
26 https://doi.org/10.1016/j.jcf.2008.09.007
27 https://doi.org/10.1016/j.jcf.2012.10.004
28 https://doi.org/10.1056/nejmoa043900
29 https://doi.org/10.1111/j.1365-2125.2012.04167.x
30 https://doi.org/10.1136/bmj.39391.713229.ad
31 https://doi.org/10.1136/thorax.56.3.218
32 https://doi.org/10.1164/rccm.200812-1845pp
33 https://doi.org/10.1183/09031936.00099506
34 https://doi.org/10.1378/chest.09-3074
35 https://doi.org/10.1378/chest.13-1926
36 https://doi.org/10.2147/ppa.s105530
37 https://doi.org/10.3310/hta17560
38 schema:datePublished 2017-06
39 schema:datePublishedReg 2017-06-01
40 schema:description BACKGROUND: Cystic fibrosis (CF) negatively impacts upon health-related quality of life and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline. OBJECTIVE: A state transition model was developed to assess the cost effectiveness of an intervention aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT). METHODS: The model estimated the costs and health outcomes for each option from the perspective of the UK National Health Service and Personal Social Services over a lifetime horizon. Health gains were valued in terms of quality-adjusted life-years (QALYs) gained. Forced expiratory volume in 1 second (FEV1) trajectories were predicted over three lung function strata: (1) FEV1 ≥70%, (2) FEV1 40-69% and (3) FEV1 <40%. Additional states were included to represent 'post-lung transplantation' and 'dead'. The model was populated using CF Registry data, literature and expert opinion. Costs were presented at 2016 values. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. RESULTS: If effective, the adherence intervention is expected to produce an additional 0.19 QALYs and cost savings of £64,078 per patient. Across all analyses, the intervention dominated current care. Over a 5-year period, the intervention is expected to generate cost savings of £49.5 million for the estimated 2979 patients with CF with Pseudomonas aeruginosa currently aged ≥16 years in the UK. If applied to a broader population of adult patients with CF receiving any nebulised therapy, the expected savings could be considerably greater. CONCLUSIONS: If effective, the adherence intervention is expected to produce additional health gains at a lower cost than current CF care. However, the economic analysis should be revisited upon completion of the full RCT. More generally, the analysis suggests that considerable gains could be accrued through the implementation of adherence interventions that shift care from expensive hospital-based rescue to community-based prevention.
41 schema:genre research_article
42 schema:inLanguage en
43 schema:isAccessibleForFree true
44 schema:isPartOf N6ee3cadc7436491786e3f42778de799a
45 Nd25a4265a2494d0d880b4b286da98ee1
46 sg:journal.1102812
47 schema:name An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis
48 schema:pagination 647-659
49 schema:productId N5b460959fbb940a892c3b607fc1d4f75
50 N9fddc92de3ef4773999fc7bb65be7458
51 Nb59ef0e15d594ab0a2a4d282cb62241d
52 Ncbd3a9529df0438eb41a72b8ea30a819
53 Nd63ef77edef04a4ea4846b9ab5359e55
54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084038600
55 https://doi.org/10.1007/s40273-017-0500-x
56 schema:sdDatePublished 2019-04-11T09:54
57 schema:sdLicense https://scigraph.springernature.com/explorer/license/
58 schema:sdPublisher N6b52d2bb7da6457eaa90db93e8cbea55
59 schema:url https://link.springer.com/10.1007%2Fs40273-017-0500-x
60 sgo:license sg:explorer/license/
61 sgo:sdDataset articles
62 rdf:type schema:ScholarlyArticle
63 N0151544d194c44fc9bef0caf5158a361 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Models, Economic
65 rdf:type schema:DefinedTerm
66 N0f4ad24473fb4633abd8fcda08579f67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Cost-Benefit Analysis
68 rdf:type schema:DefinedTerm
69 N12c70d32fdc94181abe4bcfaef08a663 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Quality of Life
71 rdf:type schema:DefinedTerm
72 N17d0863343a14300a917320c3e9a5907 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Adolescent
74 rdf:type schema:DefinedTerm
75 N198213cb69344fda8596045ea40218cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Anti-Bacterial Agents
77 rdf:type schema:DefinedTerm
78 N22d28543846b47fe81c34aa7d6d632a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Cystic Fibrosis
80 rdf:type schema:DefinedTerm
81 N2ea9f4e3ae7448d382d8be289ea48191 rdf:first sg:person.013631641755.28
82 rdf:rest Nc3a50579f04843e9995ca90919acce2a
83 N2faf5897d7244600bf0c946b1616a6e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Female
85 rdf:type schema:DefinedTerm
86 N39b78ec304fa46afaaac9a8b66243e16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Young Adult
88 rdf:type schema:DefinedTerm
89 N5b460959fbb940a892c3b607fc1d4f75 schema:name doi
90 schema:value 10.1007/s40273-017-0500-x
91 rdf:type schema:PropertyValue
92 N6b52d2bb7da6457eaa90db93e8cbea55 schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 N6ee3cadc7436491786e3f42778de799a schema:issueNumber 6
95 rdf:type schema:PublicationIssue
96 N7196a1ed932042dab5b1738d09070a8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Forced Expiratory Volume
98 rdf:type schema:DefinedTerm
99 N8076cff925f046e59e19b9562a1f6fd5 rdf:first sg:person.0670022306.41
100 rdf:rest N2ea9f4e3ae7448d382d8be289ea48191
101 N837a2b1ce1094b10b0dd1775bd06b4a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Male
103 rdf:type schema:DefinedTerm
104 N86871a48e0af422dbc6470806f7f86bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Randomized Controlled Trials as Topic
106 rdf:type schema:DefinedTerm
107 N9723ff385cd54c1e9cc29ed9092cc316 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Cost Savings
109 rdf:type schema:DefinedTerm
110 N9fddc92de3ef4773999fc7bb65be7458 schema:name dimensions_id
111 schema:value pub.1084038600
112 rdf:type schema:PropertyValue
113 Na46e39def98b48fc8bc6551976e8a2b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Medication Adherence
115 rdf:type schema:DefinedTerm
116 Nae87c0b5d8cf411ea74353b20323bd6b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 Nb59ef0e15d594ab0a2a4d282cb62241d schema:name nlm_unique_id
120 schema:value 9212404
121 rdf:type schema:PropertyValue
122 Nc2ad4dcfef2746b69b66484e3c50d02c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Pseudomonas Infections
124 rdf:type schema:DefinedTerm
125 Nc3a208fbf45f4ae0b58a7b7b16b888d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Adult
127 rdf:type schema:DefinedTerm
128 Nc3a50579f04843e9995ca90919acce2a rdf:first sg:person.01335407753.33
129 rdf:rest rdf:nil
130 Nc58d3973f2f9446f9427cf60feda74f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Quality-Adjusted Life Years
132 rdf:type schema:DefinedTerm
133 Ncbd3a9529df0438eb41a72b8ea30a819 schema:name readcube_id
134 schema:value 7790f8437bb7a467d4580bae2e758445f740ac9e3a31367a910449128367b3b1
135 rdf:type schema:PropertyValue
136 Nd25a4265a2494d0d880b4b286da98ee1 schema:volumeNumber 35
137 rdf:type schema:PublicationVolume
138 Nd63ef77edef04a4ea4846b9ab5359e55 schema:name pubmed_id
139 schema:value 28337719
140 rdf:type schema:PropertyValue
141 Nf7853111076a46048749dc88f5f849c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Pseudomonas aeruginosa
143 rdf:type schema:DefinedTerm
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
148 schema:name Public Health and Health Services
149 rdf:type schema:DefinedTerm
150 sg:grant.5149589 http://pending.schema.org/fundedItem sg:pub.10.1007/s40273-017-0500-x
151 rdf:type schema:MonetaryGrant
152 sg:journal.1102812 schema:issn 1170-7690
153 1179-2027
154 schema:name PharmacoEconomics
155 rdf:type schema:Periodical
156 sg:person.01335407753.33 schema:affiliation https://www.grid.ac/institutes/grid.31410.37
157 schema:familyName Wildman
158 schema:givenName Martin
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01335407753.33
160 rdf:type schema:Person
161 sg:person.013631641755.28 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
162 schema:familyName Sadler
163 schema:givenName Susannah
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013631641755.28
165 rdf:type schema:Person
166 sg:person.0670022306.41 schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
167 schema:familyName Tappenden
168 schema:givenName Paul
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670022306.41
170 rdf:type schema:Person
171 sg:pub.10.1007/s40265-013-0041-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023748951
172 https://doi.org/10.1007/s40265-013-0041-3
173 rdf:type schema:CreativeWork
174 sg:pub.10.1007/s40273-013-0122-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003917451
175 https://doi.org/10.1007/s40273-013-0122-x
176 rdf:type schema:CreativeWork
177 sg:pub.10.1186/1471-2288-12-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010370832
178 https://doi.org/10.1186/1471-2288-12-9
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1002/ppul.23344 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012408786
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1016/j.jcf.2008.09.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015405522
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1016/j.jcf.2012.10.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012742686
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1056/nejmoa043900 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020381896
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1111/j.1365-2125.2012.04167.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006076798
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1136/bmj.39391.713229.ad schema:sameAs https://app.dimensions.ai/details/publication/pub.1005785125
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1136/thorax.56.3.218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015966584
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1164/rccm.200812-1845pp schema:sameAs https://app.dimensions.ai/details/publication/pub.1042486144
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1183/09031936.00099506 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024574270
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1378/chest.09-3074 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006892365
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1378/chest.13-1926 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042282240
201 rdf:type schema:CreativeWork
202 https://doi.org/10.2147/ppa.s105530 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044618897
203 rdf:type schema:CreativeWork
204 https://doi.org/10.3310/hta17560 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071139376
205 rdf:type schema:CreativeWork
206 https://www.grid.ac/institutes/grid.11835.3e schema:alternateName University of Sheffield
207 schema:name ScHARR, University of Sheffield, Regent Court, 30 Regent Street, S1 4DA, Sheffield, England, UK
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.31410.37 schema:alternateName Sheffield Teaching Hospitals NHS Foundation Trust
210 schema:name Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, England, UK
211 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...